依加替莫德与静脉注射免疫球蛋白治疗老年广泛性重症肌无力的疗效及安全性比较。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology Pub Date : 2025-02-21 DOI:10.1016/j.clim.2025.110457

Chaoyue Zhang , Xiang Li , Yufei Deng , Haocheng Luo , Shuangshuang Wang , Xianni Yan , Xiaojun Yang , Qilong Jiang

{"title":"依加替莫德与静脉注射免疫球蛋白治疗老年广泛性重症肌无力的疗效及安全性比较。","authors":"Chaoyue Zhang , Xiang Li , Yufei Deng , Haocheng Luo , Shuangshuang Wang , Xianni Yan , Xiaojun Yang , Qilong Jiang","doi":"10.1016/j.clim.2025.110457","DOIUrl":null,"url":null,"abstract":"<div><div>The study examines efgartigimod and intravenous immunoglobulin (IVIg) in elderly patients with generalized myasthenia gravis (GMG), focusing on changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, pyridostigmine dosage, and minimal symptom expression (MSE) over an 8-week period. Among 74 enrolled patients, efgartigimod showed greater reduction in MG-ADL scores compared to IVIg at weeks 4 and 8, with no serious adverse events, suggesting its superior efficacy and safety in elderly Chinese patients with acetylcholine receptor antibody-positive (AChR-Ab(+)) GMG.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"274 ","pages":"Article 110457"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients\",\"authors\":\"Chaoyue Zhang , Xiang Li , Yufei Deng , Haocheng Luo , Shuangshuang Wang , Xianni Yan , Xiaojun Yang , Qilong Jiang\",\"doi\":\"10.1016/j.clim.2025.110457\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The study examines efgartigimod and intravenous immunoglobulin (IVIg) in elderly patients with generalized myasthenia gravis (GMG), focusing on changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, pyridostigmine dosage, and minimal symptom expression (MSE) over an 8-week period. Among 74 enrolled patients, efgartigimod showed greater reduction in MG-ADL scores compared to IVIg at weeks 4 and 8, with no serious adverse events, suggesting its superior efficacy and safety in elderly Chinese patients with acetylcholine receptor antibody-positive (AChR-Ab(+)) GMG.</div></div>\",\"PeriodicalId\":10392,\"journal\":{\"name\":\"Clinical immunology\",\"volume\":\"274 \",\"pages\":\"Article 110457\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521661625000324\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521661625000324","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

该研究检测了老年广发性重症肌无力（GMG）患者的艾夫加替莫德和静脉注射免疫球蛋白（IVIg），重点关注8周内重症肌无力日常生活活动（MG-ADL）评分、吡哆斯的明剂量和最小症状表达（MSE）的变化。在74例入组患者中，艾夫加替莫在第4周和第8周的MG-ADL评分较IVIg有更大的降低，未出现严重不良事件，提示其在中国老年乙酰胆碱受体抗体阳性（AChR-Ab(+)） GMG患者中具有更强的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients

The study examines efgartigimod and intravenous immunoglobulin (IVIg) in elderly patients with generalized myasthenia gravis (GMG), focusing on changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, pyridostigmine dosage, and minimal symptom expression (MSE) over an 8-week period. Among 74 enrolled patients, efgartigimod showed greater reduction in MG-ADL scores compared to IVIg at weeks 4 and 8, with no serious adverse events, suggesting its superior efficacy and safety in elderly Chinese patients with acetylcholine receptor antibody-positive (AChR-Ab(+)) GMG.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical immunology 医学-免疫学

CiteScore

12.30

自引率

1.20%

发文量

212

审稿时长

34 days

期刊介绍： Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.